摘要
基因组编辑是对基因的添加、删除或替换,以去除或启动基因组中显式和偏好的特征。利用列如CRISPR-Cas9技术这样的基因编辑工具结合基于基因的方法或基于蛋白质的技术可以实现基因组编辑,科学家们结合物理技术、病毒和非病毒策略对其进行了很长时间的研究。移植离体CRISPR编辑的细胞能够在器官移植中通过高通量和基于CRISPR的筛选来筛选单指导RNA,以验证癌细胞,包括处于其发展和治疗不同阶段的结直肠癌。CRISPR敲除筛选已经识别出人们关注的结肠癌的基因,并形成特征标记,特别是在一些具有单一向导RNA的癌细胞系中,从而揭示耐药性机制。这种方法的一个优点是处理破坏基因表达的CRISPR敲除基因组筛选,而不是大部分用RNA干扰和CRISPR/Cas技术完成的部分敲除。这种技术被用于治疗不同形式的癌症,因为它与CRISPR/Cas系统能对目标基因进行熟练的编辑。最新研究表明,CRISPR/Cas基因编辑技术从理论上改变了长非编码RNA在大肠癌中的表达。未来十年,CRISPR/Cas9技术将积极推动结肠癌更多体内基因编辑临床试验的发展,并将对分子医学产生巨大影响。
关键词: 基因组编辑、CRISPR/Cas9技术、结直肠癌、脱靶效应、分子医学、蛋白质技术。
Current Molecular Medicine
Title:Genome Editing with CRISPR-Cas9: A Budding Biological Contrivance for Colorectal Carcinoma Research and its Perspective in Molecular Medicine
Volume: 21 Issue: 6
关键词: 基因组编辑、CRISPR/Cas9技术、结直肠癌、脱靶效应、分子医学、蛋白质技术。
摘要: Genome editing is an addition, deletion, or replacement of a gene to remove or initiating explicit and preferred characters in the genome. Utilizing gene-editing tools like CRISPR-Cas9 technology could be accomplished either by gene-based methodology or protein-based technology that has been under scrutiny for the protracted time wherein physical techniques, viral and non-viral strategies have been utilized together. Transplanting ex vivo CRISPR edited cells empowers screening of single guide RNAs with high-throughput and CRISPR based screening in organoids transplantation to validate cancer cells including colorectal carcinoma in various phases of its development and treatment.CRISPR knockout screens have recognized genes that drive interest in colon cancer to develop hallmarks, especially in some cancer cell lines with single guide RNA, to disclose drug resistance mechanisms. One advantage of this method is to deal with CRISPR knockout genomic screening, which disrupts gene expression, rather than the partial knockdown that is mostly done with RNA interference and CRISPR/Cas technology. This technique is used to treat different forms of cancer because of its proficient editing of the target gene, along with the CRISPR/Cas system. Latest research has shown that the CRISPR/Cas gene-editing technique has theoretically reformed the expression in colorectal carcinoma of long non-coding RNA. For the next decade CRISPR/Cas9 technology will positively fuel the development of more in vivo gene editing clinical trials in colon cancer and will have an enormous impact on molecular medicine.
Export Options
About this article
Cite this article as:
Genome Editing with CRISPR-Cas9: A Budding Biological Contrivance for Colorectal Carcinoma Research and its Perspective in Molecular Medicine, Current Molecular Medicine 2021; 21 (6) . https://dx.doi.org/10.2174/1566524020666201119143943
DOI https://dx.doi.org/10.2174/1566524020666201119143943 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers